 This Week
in SlidesMERLIN TIMI 36 Metabolic Efficiency with Ranolazine for Less Ischemia in NSTE ACS. David Morrow, MD
TAXUS ATLAS WORKHORSE and DIRECT STENT First Report of Nine and Twelve Month Clinical and Angiographic Results. Mark A. Turco, MD and John A. Ormiston, MBChB
Randomized Early versus Late AbciXimab in Acute Myocardial Infarction treated with primary coronary intervention (RELAx-AMI Trial) Mauro Maioli, MD
Clinical Implications of Clopidogrel non-responsiveness. Dominick Angiolillo, MD, PhD
Post-Conditioning the Human Heart to Reduce Infarct Size. Michel Ovize, MD, PhD. Powerpoint Case Studies
The Good , The Bad, and The Ugly More Recent Slides COURAGE Clinical Outcomes Utilizing Revascularization and Aggressive Guideline-Driven Drug Evaluation. Bill Boden, M.D. COURAGE Design and Baseline Characteristics of the COURAGE trial by Bill Boden Dr. Bill Boden discusses the results of the COURAGE trial on C TV COURAGE Related Trials: AVERT Atorvastatin Versus Revascularization Treatments PCI vs Conservative Therapy for Chronic CAD Results from Meta-Analysis 2005
Survival PCI vs Medical Management The answer may depend on patient risk ACUITY 1 Year Results A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the ACUITY Trial. Gregg W. Stone, MD Randomized Double Blind Trial of Thrombin Receptor Antagonist (TRA) Moliterno et al
ARMYDA-ACS: Atorvastatin Pretreatment Improves Outcome in
Patients With Acute Coronary Syndromes Undergoing Percutaneous
Coronary Intervention TRIUMPH The Tilarginine Acetate Injection in a Randomized International Study in Unstable Acute Myocardial Infarction Patients with Cardiogenic Shock Trial. Judith S. Hochman, M.D. ARISE Aggressive Reduction of Inflammation Stops Events. Presented by Dr. Jean-Claude Tardif
Aliskiren and Valsartan for Antihypertensive Therapy. Presented by Dr. Suzanne Oparil ECLIPSE Blood Pressure Control with Clevidipine Compared with Nitroglycerin, Sodium Nitroprusside, or Nicardipine in the Treatment of Peri-operative Hypertension Solomon Aronson, M.D. ECLIPSE BP Control Blood Pressure Control is an Independent Predictor of Short-term Mortality in Cardiac Surgery Patients. Solomon Aronson, M.D. RACE: Reperfusion in AMI in Carolina Emergency Departments. Christopher Granger, MD. OASIS 6: Efficacy and safety of fondaparinux in elderly patients with STEMI. Ron J.G. Peters, MD. Implications of Preoperative Thienopyridine Use Prior to Coronary Bypass Graft Surgery in Patients with ACS: A Report from the ACUITY Trial. Ramin Ebrahimi, MD. ANTHEM-TIMI 32: Results of the Dose- Ranging and Heparin De-Escalation Phases of the ANTHEM-TIMI 32 Trial. Robert P. Giugliano, MD, SM. ABSORB First-ever human trial of a fully bioabsorbable everolimus-eluting stent. Presented by Dr. Patrick W. Serruys DEDICATION Distal protection using a Filterwire compared with conventional intervention among patients with STEMI undergoing PCI. Presented by Dr. Leif Thuesen. ERASE Effect of rHDL on Atherosclerosis-Safety and Efficacy. Presented by Dr. Jean-Claude Tardif. ILLUSTRATE Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation. Presented by Dr. Steven E. Nissen. METEOR Measuring Effects of Intima-Media Thickness: An Evaluation of Rosuvastatin. Presented by Dr. John R. Crouse III. View an animated presentation. View other resources NAPA Nesiritide Administered Peri-Anesthesia in Patients Undergoing Cardiac Surgery. Mark J. Russo, MD, MS.
SPIRIT III
Clinical, Angiographic, and IVUS Results from
the Pivotal U.S. Randomized SPIRIT III Trial of the XIENCE V
Everolimus-eluting Coronary Stent System. Gregg W. Stone,
MD.
FUSION II Follow-Up Serial Infusions of Nesiritide for the
Management of Patients With Heart Failure. Yancy CW et al.
Am Heart J 2007; In press.
EVEREST
Efficacy of Vasopressin antagonism in hEart failuRE: outcome
Study with Tolvaptan (EVEREST). Marvin A. Konstam, MD
|
April 24th, 2007 
Recent Television Shows April 19th, 2007 ClincialTrial Results.org Overview C. Michael Gibson, MD, MS
ClincialTrial Results.org Overview Jeffrey Popma, MD & C. Michael Gisbson, MD, MS
ClincialTrial Results.org's Year in Review 2006 Christopher Cannon, MD, Graham Turpie, MD and C. Michael Gibson, MD, MS
Dr. Gibson and Dr. Sanjay Kaul Discuss Drug Eluting Stents
April 17th, 2007 TRIP: Thrombotic Risk Progression Paul A. Gurbel, MD
Appropriate Use of Lytics: Adherence to the Guidelines W. Frank Peacock, MD
Targeting Hemoglobin and the Use of Erythropoietin and Transfusion in Cardiac Patients Peter A. McCullough, MD, MPH
AntiPlatelet Therapy in ACS and PCI Stephen D. Wiviott, MD
Incorporating Patient Risk into Decisions Regarding the Optimal Reperfusion Strategy for ST Elevation MI Duane S. Pinto, MD
Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Paul A. Gurbel, MD
Toxicity and Screening Recommendations for Amiodarone Use Peter Zimetbaum, MD
Coronary Revascularization in Diabetic Patients - Optimizing Outcomes in 2007 David J. Cohen, MD, MSc
April 16th, 2007 REPLACE-II and ACUITY: Transitioning Between Antithrombins in the Cath Lab C. Michael Gibson, MS, MD
Pay For Performance: What Does it Mean, What will be its Impact in CV Care James Hoekstra, MD
Pretreatment with Thienopyridines C. Michael Gibson, MS, MD
Prognostic Implication of Bleeding and Transfusions in ACS and PCI Steven V. Manoukian, MD
LDL or HDL: Which is More Important? Christopher P. Cannon, MD
Results from ANTHEM: A Phase 2 Heparin Replacement Trial Evaluating rNAPc2 in ACS Robert P. Giugliano, MD, SM
OASIS 6: Efficacy and Safety of Fondaparinux in Elderly Patients With STEMI Ron J.G. Peters, MD
April 9th, 2007
STARR: The Study of Atherosclerosis with Ramipril and Rosiglitazone Eva M. Lonn, MD
TRIP: Thrombotic Risk Progression Paul A. Gurbel, MD
|
Hello from clinical
trial results Dr Michael Nguyen Editor
Clinicaltrialresults.org
|
.wmv